Mood and Reward

Possibility to get experience from clinical drug trials, perform epidemiological studies (primarily within pharmacoepidemiology), and conduct systematic reviews and/or meta-analyses on psychotropic drugs

Hippocampal synaptic transmission and plasticity, AMPA receptors, astrocytic modulation, rodent models of brain disorders, depression and the GABAergic system, excitatory-inhibitory imbalances

My research is on social and emotional functioning and sleep, particularly in the postnatal period.

We study the neurobiological basis of decision-making and learning in humans. We use behavioural testing, computational modelling, functional MRI and electrochemical recordings of neuromodulatory systems in awake brain surgery patients.

We investigate the neurobiology of psychiatric disorders with the aim to identify novel treatment targets. We use different animal models, cell culture, mol. biology (qPCR, WB, Elisa), neurochemistry, confocal microscopy and pharmacological assays.

Molecular neuropharmacology – understanding the method of action of psychotropic drugs such as hallucinogens and antidepressants with their target (transporters and receptors). Special interest in studying the serotonergic and dopaminergic systems.

Identification of biomarkers and novel treatment strategies within mental disorders. Rodent models and human tissue are used to identify relevant mRNA/non-coding RNAs (real-time qPCR, Nanostring, ISH) and proteins (ELISA, Luminex, IHC).

Advanced in vivo modeling of Psychiatric disorders, behaviour, neurochemistry, stereology and viral vector techniques. Neuroinflammation. Dietary factors in mental health disease. Screening and mechanisms of new drug candidates.

Our overall aim is to improve the understanding of molecular mechanisms underlying psychiatric disease. We are specifically interested in the relationship between inflammatory processes and psychiatric disease with a view to develop alternative treat

In our research group we aim to develop clinical decision support tools for psychiatry using state-of-the-art machine learning methods. For more information, see: https://pubmed.ncbi.nlm.nih.gov/34369330/

We purify neurotransmitter transport proteins for structure-function studies. Use cryo-EM, fluorescence, nanodiscs, liposomes and molecular pharmacology e.g. binding sites for cocaine or novel compounds. You will join a fun and vibrant lab.

My lab investigates the brain’s reward system: how does it work, and why? We explore computational theories that constrain how it should work and then test the predictions of these theories against behavioural, hormonal, physiological, & neural data.

Application of medical image processing and machine learning to clinical medical image data & Open science and data sharing initiatives

The research in my group evolves around deciphering the immune-to-brain mechanisms and neural circuits of affective disorders. We are working on uncovering the mechanisms responsible for pathologies using state-of-the-art circuit techniques

I apply human functional (fMRI) and molecular (PET) brain imaging to map brain mechanisms of behavior and effects of pharmacological interventions. My research focuses largely on serotonin signaling, including acute/lasting effects of psychedelics.

Ethologically valid rodent behavioral models for psychiatric disorders to point at new druggable targets. Neuroplasticity and dopaminergic/muscarinergic interactions. Genetically modified rodents, viral vectors, neuropharmacology.

Development of neuroactive ligands. Drug design, organic synthesis, ligand development.

The research focuses on cellular actions of drugs of abuse in motivation and reward/arousal regions which are involved in assigning saliency to drugs which are abused, and which exhibit addictive properties. We use mouse models of addiction.

I seek to understand changes that occur in alcohol and substance use disorder to identify and validate new pharmacotherapies. We currently work on muscarinic cholinergic, GLP-1, and ketogenic approaches

Brain architecture of risk and resilience for mood disorders and neurodegenerative disorders; particularly serotonergic and steroid hormone contributions. I use an integrated molecular imaging approach and work with clinical translations.

I use neurophenomenology and psychometrics to study effects of classic psychedelic drugs, e.g., psilocybin and LSD. I furthermore develop and test psychological interventions for use during psychedelic therapy.

Hepatic remote control of alcohol drinking; mass spectrometry, intersectional chemogenetics, metabolism, behavior

We develop and investigate the effects of new ligands targeting the 5-HT2AR receptor, the principal mediator of the subjective and therapeutic effects of Psychedelics. Primary focus on ligand design and synthesis.

I do data-driven research and drug design on G protein-coupled receptors that mediate the effects of 2/3rd of hormones and 1/3rd of drugs. With a creative interdisciplinary approach we discover receptor systems and mechanisms for safer drugs.

We develop novel modulators of neurotransmitter receptors, study the molecular basis for structure/function aspects of these receptors and for their modulation, and explore physiological functions of the receptors using the developed modulators.

The NEAD Group conducts clinical experimental studies in mood disorders using neurocognitive tests, clinical ratings and neuroimaging to identify novel treatments that reduce illness risk or target cognitive impairment and to explore their mechanisms

Brain imaging and neuropsychological research of predictors of effect and adverse effects of Electroconvulsive treatment for severe depression

Chair of the Copenhagen Affective Disorder research Center (CADIC). Dr. Scientific contributions within clinical, epidemiological including register-based, genetic and neurobiological research in bipolar and unipolar affective disorders.

Molecular and cellular function of monoamine receptors and transporters; dopamine pharmacology and physiology; dopamine disease biology and genetics (substance use disorder, ADHD, schizophrenia, parkinsonism)

Rodent models of obsessive-compulsive disorder, analysis of rodent compulsive behaviors, reversal learning and stereotypic grooming, functional neuroimaging, neuronal circuits, and the actions of psychedelic and empathogenic drugs.